Members

Transdermal Drug Delivery System Market worth $7.1 billion by 2023 - Exclusive Report by MarketsandMarkets™

The transdermal drug delivery system market is expected to reach USD 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period (2018-2023), according to a new report by MarketsandMarkets™. Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are also expected to support market growth in the coming years.

Browse in-depth TOC on "Transdermal Drug Delivery System Market”
71 – Tables
35 – Figures
133 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203190114

The pain management segment is expected to account for the largest share of the market in 2018

On the basis of application, the market is segmented into pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications (smoking cessation, motion sickness, and overactive bladder treatment). In 2018, the pain management segment is expected to account for the largest share of the transdermal drug delivery systems market. Growth in this market is largely driven by the high burden of chronic pain worldwide and the growing availability of transdermal products for pain management.

The transdermal patches segment is expected to grow at the highest CAGR during the forecast period

On the basis of type, the transdermal drug delivery system market is segmented into transdermal patches and transdermal semisolids. In 2018, the transdermal patches segment is expected to account for the larger share of the transdermal drug delivery systems market. This drug delivery system offers several advantages, such as reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point by the removal of the patch. Also, the use of patches results in increased patient compliance due to their non-invasive nature and painless application. These factors are expected to drive market growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=203190114

North America to dominate the transdermal drug delivery system market in 2018

North America is expected to dominate the transdermal drug delivery system market in 2018. The large share of the North American transdermal drug delivery systems market can primarily be attributed to the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.

The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).

Browse Adjacent Market: Pharmaceuticals Market Research Reports & Consulting

Related Reports:

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027
https://www.marketsandmarkets.com/Market-Reports/topical-drug-deliv...

Views: 9

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2022   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service